International Cancer Proteogenome Consortium

The International Cancer Proteogenome Consortium (ICPC), is a voluntary scientific organization that provides a forum for collaboration among some of the world’s leading cancer and proteogenomic research centers.  Catalyzed by the effort of the Cancer Moonshot to encourage international cooperation and investments among nations in cancer research and care, as well as new efforts in precision medicine, the International Cancer Proteogenome Consortium (ICPC) was launched in late 2016.  The ICPC brings together more than a dozen countries to study the application of proteogenomic analysis in predicting cancer treatment success and to share data and results with researchers worldwide, hastening progress for patients.

Intrahepatic Cholangiocarcinoma
System:
Liver
Jurisdiction:
China
Cutaneous Melanoma
System:
Skin
Jurisdiction:
Sweden
Pancreatic Ductal Adenocarcinoma
System:
Pancreas
Jurisdiction:
United States
Lung Squamous Cell Carcinoma
System:
Lung
Jurisdiction:
United States
Glioblastoma Multiforme
System:
Brain
Jurisdiction:
United States
Pediatric Brain Cancer
System:
Brain
Jurisdiction:
United States
Breast Cancer
System:
Breast
Jurisdiction:
United States
HPV-negative HNSCC
System:
Head and Neck
Jurisdiction:
United States
Oral Squamous Cell Carcinoma
System:
Head and Neck
Jurisdiction:
Taiwan
HBV+ Hepatocellular Carcinoma
System:
Liver
Jurisdiction:
China
Lung Adenocarcinoma
System:
Lung
Jurisdiction:
Taiwan
Early-onset Gastric Cancer
System:
Stomach
Jurisdiction:
South Korea
Colon Adenocarcinoma
System:
Intestine
Jurisdiction:
United States
Ovarian High-Grade Serous Cancer
System:
Ovary
Jurisdiction:
United States
Lung Adenocarcinoma
System:
Lung
Jurisdiction:
United States
Uterine Corpus Endometrial Carc
System:
Uterus
Jurisdiction:
United States
Clear Cell Renal Cell Carcinoma
System:
Kidney
Jurisdiction:
United States
x